<code id='5B72640332'></code><style id='5B72640332'></style>
    • <acronym id='5B72640332'></acronym>
      <center id='5B72640332'><center id='5B72640332'><tfoot id='5B72640332'></tfoot></center><abbr id='5B72640332'><dir id='5B72640332'><tfoot id='5B72640332'></tfoot><noframes id='5B72640332'>

    • <optgroup id='5B72640332'><strike id='5B72640332'><sup id='5B72640332'></sup></strike><code id='5B72640332'></code></optgroup>
        1. <b id='5B72640332'><label id='5B72640332'><select id='5B72640332'><dt id='5B72640332'><span id='5B72640332'></span></dt></select></label></b><u id='5B72640332'></u>
          <i id='5B72640332'><strike id='5B72640332'><tt id='5B72640332'><pre id='5B72640332'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:4157
          Cambridge: Biogen
          Ruby Wallau for STAT

          Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.

          Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.

          advertisement

          “It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          A Q&A with the global head of Boehringer Ingelheim's innovation unit
          A Q&A with the global head of Boehringer Ingelheim's innovation unit

          MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Clinical trials giant ICON acquires HumanFirst

          AdobeAspharmacompanieswrestlewithhowandwhentousewearablesandotherdigitaltechnologiestomeasurehowthei